Loading
A phase 2 trial of Volrustomig in cervical cancer, run by AstraZeneca, active and no longer recruiting.
A Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA) is a phase 2 interventional study registered as NCT06943833 by AstraZeneca, with 37 participants enrolled, started 2025-03-31 and due to reach its primary completion in 2028-03-13. Interventions recorded: Volrustomig.
Shares Locally advanced cervical cancer, AstraZeneca, Cervical cancer and the tag pipeline.
Shares Locally advanced cervical cancer, Cervical cancer and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares Cervical cancer and the tag pipeline.